InTandem Capital Partners, a NYC-based middle-market private equity firm focused exclusively on healthcare services, closed InTandem Capital Partners Fund III, LP, with $715m in total capital commitments.
Fund III secured commitments from a globally diversified group of existing and new investors, including leading endowments, foundations, family offices, healthcare and pension systems, and financial institutions.
Consistent with its predecessor funds, Fund III will continue the firm’s established strategy of making control investments in North American payor, provider, and pharmaceutical services businesses using an operationally intensive, hands-on value creation model. InTandem partners closely with founders, entrepreneurs and management teams to accelerate transformational growth.
The fund is already actively investing, having recently completed its third platform deal in Adams Clinical, a multi-site clinical research management organization focused on late-stage outpatient central nervous system trials.
Led by Elliot Cooperstone, Managing Partner, Brad Coppens, Senior Partner, and Lauren Mangino, Principal and Head of Investor Relations and Capital Formation, among others, InTandem Capital Partners is a private equity firm that invests in and helps accelerate the growth of select healthcare services companies. InTandem is focused on investing in businesses that align with the Healthcare Quintuple Aim – the simultaneous pursuit of enhanced patient experience, elevated provider experience, improved clinical outcomes, greater healthcare equity, and lower cost of care delivery.
FinSMEs
12/06/2024